Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.

Lung cancer (Amsterdam, Netherlands) - 1 Dec 2023

Nützinger Jorn, Bum Lee Jii, Li Low Jia, Ling Chia Puey, Talisa Wijaya Silvana, Chul Cho Byoung, Min Lim Sun, Soo Ross A

Abstract excerpt

HER2 mutations, which account for 2-4% of non-small cell lung cancer (NSCLC), are distinct molecular alterations identified via next generation sequencing (NGS). Previously, treatment outcomes in HER2-mutant metastatic NSCLC were dismal, showing limited clinical benefit with platinum-based chemotherapy with or without immunotherapy. In contrast to HER2-altered breast and gastric cancer, HER2-mutant NSCLC does not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Identifiers

PMID: 37813015
DOI: 10.1016/j.lungcan.2023.107385

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.PMID 37813015Read ↗

HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape.Semantic proximity Read ↗

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging TherapiesSemantic proximity Read ↗

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.Semantic proximity Read ↗

Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability.Semantic proximity Read ↗

Targeting HER2 in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.Semantic proximity Read ↗

[Current management and future prospect of HER-2 mutant non-small cell lung cancer].Semantic proximity Read ↗

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].Semantic proximity Read ↗

HER2 and lung cancer.Semantic proximity Read ↗

HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.